A preview of an article about an early-stage cardiovascular drug trial, outlining the study’s design and what readers can expect to learn.
Key Takeaways
- BioAge has dosed the first participant in a randomized, double-blind, placebo-controlled Phase 2 trial
- Investigational oral small molecule is a brain-penetrant NLRP3 inhibitor described as structurally novel
- Trial is dose-ranging and positioned as a proof-of-concept study for cardiovascular risk reduction